Product Details

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Pembrolizumab making it ideal for research use. This Pembrolizumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being used as cancer treatments. Pembrolizumab binds to PD-1 on activated immune cells to selectively block the interaction of PD-1 with its ligands.

RMP1-14單克隆抗體與小鼠PD-1（程序性死亡-1）反應(yīng)，也稱為CD279。PD-1是由Pdcd50基因編碼的55-1 kDa細(xì)胞表面受體，屬于Ig超家族的CD28家族。PD-1在CD4和CD8胸腺細(xì)胞以及活化的T和B淋巴細(xì)胞和骨髓細(xì)胞上短暫表達(dá)。PD-1在成功消除抗原后表達(dá)下降。此外，Pdcd1 mRNA在前B細(xì)胞階段的發(fā)育B淋巴細(xì)胞中表達(dá)。

BioXCell艾美捷體內(nèi)單克隆抗小鼠 PD-1(CD279)抗體規(guī)格：

#  BXC-BE0146

Isotype Human IgG4

Recommended Isotype Control(s) RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme

Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer

Immunogen Human PD-1

Reported Applications Blocking of PD-1/PD-L signaling

Functional assays

Formulation PBS, pH 7.0

Contains no stabilizers or preservatives

Endotoxin <1EU/mg (<0.001EU/μg)

Determined by LAL gel clotting assay

Aggregation <5%

Determined by DLS

Purity >95%

Determined by SDS-PAGE

Sterility 0.2 μM filtered

Production Purified from cell culture supernatant

Purification Protein A

RRID AB_2894731

Molecular Weight 150 kDa

Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.

同種型 大鼠IgG2a， κ

推薦的同種型對(duì)照 體內(nèi)MAb大鼠IgG2a同種型對(duì)照，抗三-硝-基-苯-酚

推薦的稀釋緩沖液 體內(nèi)純 pH 7.0 稀釋緩沖液

免疫原 用小鼠PD-1 cDNA轉(zhuǎn)染的敘利亞倉鼠BKH細(xì)胞

報(bào)告的應(yīng)用程序 PD-1/PD-L信號(hào)傳導(dǎo)的體內(nèi)阻斷

配方 PBS，pH 7.0

不含穩(wěn)定劑或防腐劑

內(nèi)毒素 <2EU/mg （<0.002EU/μg）

通過LAL凝膠凝血測(cè)定法測(cè)定

純度 >95%

由 SDS-PAGE 決定

無 菌 0.2 μM 過濾

生產(chǎn) 從無動(dòng)物設(shè)施中的組織培養(yǎng)上清液中純化

純化 蛋白 G

里德 AB_10949053

分子量 150 千達(dá)

存儲(chǔ) 抗體溶液應(yīng)以4°C的儲(chǔ)備濃度儲(chǔ)存。 不要凍結(jié)。